|
JP6047270B2
(ja)
|
2006-08-11 |
2016-12-21 |
バイオマリン テクノロジーズ ベー．フェー． |
Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
|
|
NZ584793A
(en)
|
2007-10-26 |
2012-05-25 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
ES2756326T3
(es)
|
2010-07-19 |
2020-04-27 |
Ionis Pharmaceuticals Inc |
Modulación de la expresión de distrofia miotónica-proteína quinasa (DMPK)
|
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
EP3702460A1
(en)
|
2010-11-12 |
2020-09-02 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
|
US8569254B2
(en)
|
2010-12-10 |
2013-10-29 |
National Yang Ming University |
Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same
|
|
AU2012246822B2
(en)
*
|
2011-04-22 |
2017-05-25 |
Biomarin Technologies B.V. |
New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (DM1)
|
|
EP2751269B1
(en)
|
2011-08-29 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
|
CA2862628C
(en)
|
2012-01-27 |
2021-08-24 |
Prosensa Technologies B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
EP3330278A1
(en)
*
|
2012-02-08 |
2018-06-06 |
Ionis Pharmaceuticals, Inc. |
Modulation of rna by repeat targeting
|
|
PT2841578T
(pt)
*
|
2012-04-23 |
2017-08-10 |
Biomarin Tech Bv |
Resumo
|
|
EA201492120A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии atp2a2
|
|
JP2015523854A
(ja)
|
2012-05-16 |
2015-08-20 |
ラナ セラピューティクス インコーポレイテッド |
Ｓｍｎ遺伝子ファミリー発現を調節するための組成物及び方法
|
|
CN104583402A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节mecp2表达的组合物和方法
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
CN104540946A
(zh)
|
2012-05-16 |
2015-04-22 |
Rana医疗有限公司 |
用于调节utrn表达的组合物和方法
|
|
US10174315B2
(en)
|
2012-05-16 |
2019-01-08 |
The General Hospital Corporation |
Compositions and methods for modulating hemoglobin gene family expression
|
|
US10029916B2
(en)
|
2012-06-22 |
2018-07-24 |
C3Nano Inc. |
Metal nanowire networks and transparent conductive material
|
|
CN104603271B
(zh)
|
2012-07-03 |
2019-07-19 |
马林生物科技有限公司 |
用于治疗肌肉萎缩症患者的寡核苷酸
|
|
KR20150037968A
(ko)
|
2012-07-12 |
2015-04-08 |
프로큐알 테라퓨틱스 엔.브이. |
살아있는 세포 내에 존재하는 목적 rna 분자의 서열을 변화시키기 위한 올리고뉴클레오타이드
|
|
US10020807B2
(en)
|
2013-02-26 |
2018-07-10 |
C3Nano Inc. |
Fused metal nanostructured networks, fusing solutions with reducing agents and methods for forming metal networks
|
|
JP6487913B2
(ja)
*
|
2013-07-02 |
2019-03-20 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
成長ホルモン受容体のモジュレータ
|
|
EP3027617B1
(en)
*
|
2013-07-31 |
2026-02-18 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
SI3119888T1
(sl)
|
2014-03-19 |
2021-11-30 |
Ionis Pharmaceuticals, Inc. |
Sestavki za moduliranje izražanja ataksina 2
|
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
|
WO2015168618A2
(en)
|
2014-05-01 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating growth hormone receptor expression
|
|
WO2016070060A1
(en)
|
2014-10-30 |
2016-05-06 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
|
US10900036B2
(en)
|
2015-03-17 |
2021-01-26 |
The General Hospital Corporation |
RNA interactome of polycomb repressive complex 1 (PRC1)
|
|
EA201792261A1
(ru)
|
2015-05-29 |
2018-04-30 |
Зе Боард Оф Трастис Оф Зе Лилэнд Стэнфорд Джуниор Юниверсити |
Нуклеозидные вещества для уменьшения вредной активности генов, содержащих удлиненные нуклеотидные повторы
|
|
US10696664B2
(en)
*
|
2015-08-14 |
2020-06-30 |
Merck Patent Gmbh |
Phenoxazine derivatives for organic electroluminescent devices
|
|
CA3119019C
(en)
|
2015-12-10 |
2024-06-11 |
Ptc Therapeutics, Inc. |
Compounds and methods for treating huntington's disease
|
|
WO2017117496A1
(en)
|
2015-12-31 |
2017-07-06 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing ataxin-2 expression
|
|
AU2017291960B2
(en)
|
2016-07-05 |
2024-03-14 |
Biomarin Technologies B.V. |
Pre-mRNA splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders
|
|
JOP20190104A1
(ar)
*
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
BR112019009953A2
(pt)
|
2016-11-16 |
2019-10-08 |
Academisch Ziekenhuis Leiden |
substâncias direcionadas a vários órgãos ou tecidos selecionados
|
|
US20180193270A1
(en)
|
2016-11-29 |
2018-07-12 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
US11268093B2
(en)
|
2017-01-03 |
2022-03-08 |
Rula Zain-Luqman |
Therapeutic method for huntington's disease
|
|
WO2018165541A1
(en)
*
|
2017-03-10 |
2018-09-13 |
The Board Of Regents Of The University Of Texas System |
Treatment of fuchs' endothelial corneal dystrophy
|
|
EP4151627A1
(en)
|
2017-06-05 |
2023-03-22 |
PTC Therapeutics, Inc. |
Compounds for treating huntington's disease
|
|
CN111163838B
(zh)
|
2017-06-28 |
2023-03-28 |
Ptc医疗公司 |
用于治疗亨廷顿氏病的方法
|
|
CN111182898B
(zh)
|
2017-06-28 |
2024-04-16 |
Ptc医疗公司 |
用于治疗亨廷顿氏病的方法
|
|
US11512327B2
(en)
|
2017-08-03 |
2022-11-29 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of AAV
|
|
BR112020019373A2
(pt)
|
2018-03-27 |
2020-12-29 |
Ptc Therapeutics, Inc. |
Compostos para o tratamento da doença de hutington
|
|
IL279688B2
(en)
|
2018-06-27 |
2025-01-01 |
Ptc Therapeutics Inc |
Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
|
|
KR20210038845A
(ko)
|
2018-06-27 |
2021-04-08 |
피티씨 테라퓨틱스, 인크. |
헌팅턴병 치료를 위한 헤테로아릴 화합물
|
|
AU2019310097A1
(en)
|
2018-07-25 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ATXN2 expression
|
|
US12331293B2
(en)
|
2018-11-02 |
2025-06-17 |
Biomarin Technologies B.V. |
Bispecific antisense oligonucleotides for dystrophin exon skipping
|
|
CA3139821A1
(en)
|
2019-05-13 |
2020-11-19 |
Ptc Therapeutics, Inc. |
Compounds for treating huntington's disease
|
|
TW202131920A
(zh)
|
2019-11-01 |
2021-09-01 |
瑞士商諾華公司 |
剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
|
|
WO2022069511A1
(en)
|
2020-09-30 |
2022-04-07 |
Biomarin Technologies B.V. |
Antisense oligonucleotides targeting the exon 51 of dystrophin gene
|
|
TW202304446A
(zh)
|
2021-03-29 |
2023-02-01 |
瑞士商諾華公司 |
剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
|
|
US11833221B2
(en)
|
2021-09-01 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds for reducing DMPK expression
|
|
AU2023245901A1
(en)
|
2022-03-30 |
2024-10-03 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
|
JP2026516311A
(ja)
|
2023-04-24 |
2026-05-21 |
バイオマリン ファーマシューティカル インコーポレイテッド |
Ｓｔｘｂｐ１障害を治療するための組成物および方法
|
|
WO2024233303A1
(en)
|
2023-05-05 |
2024-11-14 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
|
WO2026077951A1
(en)
|
2024-10-07 |
2026-04-16 |
Vico Therapeutics B.V. |
Improved aon for rna editing
|
|
WO2026099473A1
(en)
|
2024-11-08 |
2026-05-15 |
Vico Therapeutics B.V. |
Oligonucleotides with new internucleoside linkage
|
|
WO2026125419A1
(en)
|
2024-12-12 |
2026-06-18 |
Vico Therapeutics B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
|